Hypha LabsFUNI EBITDA Margin % is 0.00% as of Mar. 2026. The stock has 2 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Hypha Labs ranks worse than 490195.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Hypha Labs's EBITDA for the
three
months ended in Mar. 2026 was $-0.41 Mil. Hypha Labs's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Hypha Labs's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hypha Labs EBITDA Margin % Related Terms
Hypha Labs EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Hypha Labs's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FUNI vs IVRO, IDTA, NSTM: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Hypha Labs's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hypha Labs EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hypha Labs's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hypha Labs's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hypha Labs (FUNI) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hypha Labs and its competitors. According to the industry distribution chart, Hypha Labs ranks #999999 out of 204 companies in the Medical Diagnostics & Research industry.
Is Hypha Labs' EBITDA Margin % too high?
Hypha Labs' current EBITDA Margin % is 0.00%. Based on the distribution chart, Hypha Labs ranks #999999 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Hypha Labs' EBITDA Margin % compare to IVRO and IDTA?
According to the Medical Diagnostics & Research industry distribution chart, Hypha Labs ranks #999999 out of 204 companies for EBITDA Margin %. This places Hypha Labs in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hypha Labs and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hypha Labs's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hypha Labs stock overvalued right now?
Hypha Labs (FUNI) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hypha Labs (FUNI), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hypha Labs Inc engaged in the research, development, and commercialization of the Hypha Micropearl accelerator, an in-home, web-based, computer-controlled bioreactor designed to accelerate the production of nutritionally beneficial mushrooms for human consumption. The Company's easy-to-use device, together with replaceable cartridges ordered through its exclusive app, safely and effectively produced enriched mycelium of functional mushrooms, or Micropearls, in eight days. These Micropearls contained active mushroom ingredients in a concentrated, easy-to-handle, tasteless, and odorless form that could be incorporated into various foods and beverages without altering flavor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FUNI has been successfully added to your 